8-K: Soleno Therapeutics Reports Strong Preliminary 2025 Results

Soleno Therapeutics announced preliminary unaudited financial and operating results for Q4 and full-year 2025, highlighting strong VYKAT XR sales and market penetration.

Summary

• Preliminary unaudited full-year 2025 net revenue from VYKAT XR U.S. sales is expected to be between $189 million and $191 million.
• Preliminary unaudited fourth quarter 2025 net revenue is expected to be between $90 million and $92 million.
• Total new patient start forms for VYKAT XR reached 1,250 from launch through December 31, 2025, with 207 in the fourth quarter alone.
• Patient start forms represent approximately 12.5% of the total U.S. VYKAT XR addressable market for Prader-Willi syndrome.
• The discontinuation rate for VYKAT XR due to adverse events was approximately 12% as of the end of the fourth quarter.
• The company has 630 unique prescribers, including 136 new prescribers added in the fourth quarter.
• VYKAT XR coverage extends to over 185 million lives, representing approximately 60% of total lives.
• Soleno Therapeutics has achieved profitability and positive cash flow.
• Year-end 2025 cash, cash equivalents, and marketable securities were approximately $500 million, following a $100 million accelerated share repurchase program announced on November 11, 2025.
• The company has responded to Day 120 questions received from the European Medicines Agency.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results, significant market penetration for its key product VYKAT XR, achievement of profitability and positive cash flow, and a robust cash position. These are all highly positive indicators for a biopharmaceutical company post-launch, despite the standard risks associated with drug development and commercialization.

Positives

• Strong preliminary full-year 2025 net revenue guidance of $189 million to $191 million for VYKAT XR U.S. sales.
• Robust preliminary fourth quarter 2025 net revenue guidance of $90 million to $92 million.
• Significant market penetration with 1,250 total new patient start forms, representing approximately 12.5% of the U.S. addressable market for VYKAT XR in less than nine months since launch.
• Expansion of prescriber base to 630 unique prescribers, with 136 new prescribers in Q4 2025.
• Broad payer coverage, with over 185 million lives covered, or approximately 60% of total lives.
• Achievement of profitability and positive cash flow.
• Strong cash position with approximately $500 million in cash, cash equivalents, and marketable securities at year-end 2025, even after a $100 million accelerated share repurchase.
• Progress with European regulatory process by responding to Day 120 questions from the European Medicines Agency.

Negatives

• The discontinuation rate of VYKAT XR related to adverse events was approximately 12% as of the end of the fourth quarter.

Risks

• Preliminary financial information is unaudited and does not present all information necessary for a full understanding of the financial condition.
• The estimates are subject to a number of risks, uncertainties, and assumptions, and actual results could differ materially from those projected.
• VYKAT XR has contraindications, including known hypersensitivity to diazoxide, other components, or thiazides.
• Warnings and precautions include the risk of hyperglycemia, including diabetic ketoacidosis, requiring regular monitoring of fasting plasma glucose and HbA1c.
• Risk of fluid overload and edema, requiring monitoring for signs or symptoms, especially in patients with compromised cardiac reserve.
• Common adverse reactions include hypertrichosis, edema, hyperglycemia, and rash.

Future Outlook

The company anticipates continued growth in VYKAT XR sales by raising awareness of the treatment for hyperphagia in Prader-Willi syndrome, aiming to impact more patients and create sustained company value. Full audited financial results for the fourth quarter and full-year 2025 are expected to be announced in late February 2026.

Management Comments

• "Our strong fourth quarter results cap a truly transformational year for Soleno Therapeutics, driven by the approval and successful launch of VYKAT XR in the U.S."
• "In less than nine months since launch, we have received patient start forms representing well over 10% of our addressable U.S. Prader-Willi syndrome (PWS) patient population."
• "This reflects the significant unmet medical need that VYKAT XR can address as well as our success in communicating VYKAT XRs value proposition to payers, providers and caregivers."
• "Looking ahead, as we continue to raise awareness of this first-to-market hyperphagia treatment, we have the opportunity to significantly impact the lives of many more patients and families living with PWS while simultaneously creating sustained value for our company."
• "We are well-funded, our leading indicators are strong, and I am excited for what the future holds in 2026 and beyond."

Industry Context

Soleno Therapeutics operates in the rare disease biopharmaceutical sector, specifically targeting Prader-Willi syndrome (PWS) with VYKAT XR, the first-to-market hyperphagia treatment. The successful launch and rapid market penetration, reaching 12.5% of the addressable U.S. PWS patient population in under nine months, demonstrate strong execution in a niche market with significant unmet medical need. Achieving profitability and positive cash flow shortly after launch is a notable accomplishment in the often capital-intensive biopharmaceutical industry, especially for a rare disease drug.

Comparison to Industry Standards

• Achieving profitability and positive cash flow within nine months of a major drug launch is significantly better than many biopharmaceutical companies, which often operate at a loss for several years post-launch due to high R&D and commercialization costs.
• Capturing 12.5% of an addressable market for a rare disease drug in less than nine months post-launch is a strong indicator of successful market access and physician adoption, often exceeding initial expectations for orphan drugs.
• The 12% discontinuation rate due to adverse events is a key metric for drug tolerability; while not explicitly compared to industry benchmarks in the filing, it provides a baseline for future performance evaluation against similar rare disease treatments.
• The rapid expansion of payer coverage to 60% of total lives (over 185 million) is a strong performance metric, indicating effective market access strategies compared to the often challenging reimbursement landscape for new, high-cost rare disease therapies.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, profitability, positive cash flow, significant market penetration of VYKAT XR, and a $100 million accelerated share repurchase program, indicating confidence in future value.
• Patients and Families (Prader-Willi Syndrome): Positive impact as VYKAT XR addresses a significant unmet medical need for hyperphagia, with increasing access through new patient starts and broad payer coverage.
• Healthcare Providers/Prescribers: Positive impact through the availability of a first-to-market treatment for hyperphagia in PWS, supported by a growing base of unique prescribers.
• Employees: Positive impact from the company's strong financial health, profitability, and growth trajectory, suggesting job security and potential for future opportunities.

Next Steps

• Announce full fourth quarter and full-year 2025 financial results in late February 2026.
• Continue to raise awareness of VYKAT XR to impact more patients and families living with Prader-Willi syndrome.
• Continue efforts to create sustained value for the company.

Key Dates

Recommendation

The preliminary results indicate exceptional performance for Soleno Therapeutics, particularly given the relatively short time since VYKAT XR's launch. Achieving profitability and positive cash flow, coupled with robust revenue figures ($189M-$191M full-year, $90M-$92M Q4) and significant market penetration (12.5% of addressable market, 1,250 patient starts) in less than nine months, demonstrates strong commercial execution and addresses a critical unmet medical need. The substantial cash reserves ($500M) after a $100M share repurchase further strengthen the company's financial position and signal management's confidence. While a 12% discontinuation rate exists, the overall trajectory and leading indicators are highly positive, suggesting significant future growth potential and sustained value creation. This performance significantly exceeds typical expectations for a biopharmaceutical company post-launch, warranting a 'strong buy' recommendation.

Keywords

Soleno Therapeutics, SLNO, VYKAT XR, Prader-Willi Syndrome, PWS, Hyperphagia, Rare Disease, Biopharmaceutical, Preliminary Results, Financial Performance, Drug Launch, FDA Approved, Pharmaceutical Sales, Cash Flow, Profitability, Share Repurchase